“Ukatamanga weka utamangisa, tikatamanga awili, tifikapatali - When you run alone, you run fast. When you run together, you run far Zambian Proverb

UNZA-UCLMS

Research and Training Programme

2015

Criteria for discharge of patients with Ebola virus diseases in high-income countries. Bevilacqua N, Nicastri E, Chinello P, Puro V, Petrosillo N, Caro AD, Capobianchi MR, Lanini S, Vairo F, Pletschette M, Zumla A, Ippolito G; INMI Ebola Team. Lancet Glob Health. 2015 Oct 21.


Delamanid expanded access novel treatment of drug resistant tuberculosis. Rustomjee R, Zumla A. Infect Drug Resist. 2015 Oct 29;8:359-66.


Blood kinetics of Ebola virus in survivors and nonsurvivors. Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A, Langer M, Kabia S, Brogiato G, Amone J, Castilletti C, Miccio R, Zumla A, Capobianchi MR, Di Caro A, Strada G, Ippolito G; INMI-EMERGENCY EBOV Sierra Leone Study Group. J Clin Invest. 2015 Dec;125(12):4692-8.


Rapid infectious diseases diagnostics using Smartphones. Bates M, Zumla A. Ann Transl Med. 2015 Sep;3(15):215. 


Update in Mycobacterium tuberculosis Lung Disease 2014. Elkington P, Zumla A. Am J Respir Crit Care Med. 2015 Oct 1;192(7):793-8.


Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done. Schito M, Maeurer M, Kim P, Hanna D, Zumla A. Clin Infect Dis. 2015 Oct 15;61(suppl 3):S95-S101.


B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis. Rao M, Valentini D, Poiret T, Dodoo E, Parida S, Zumla A, Brighenti S, Maeurer M. Clin Infect Dis. 2015 Oct 15;61(suppl 3):S225-S234.


T-Cell Therapy: Options for Infectious Diseases. Parida SK, Poiret T, Zhenjiang L, Meng Q, Heyckendorf J, Lange C, Ambati AS, Rao MV, Valentini D, Ferrara G, Rangelova E, Dodoo E, Zumla A, Maeurer M. Clin Infect Dis. 2015 Oct 15;61(suppl 3):S217-S224.


Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Schito M, Migliori GB, Fletcher HA, McNerney R, Centis R, D'Ambrosio L, Bates M, Kibiki G, Kapata N, Corrah T, Bomanji J, Vilaplana C, Johnson D, Mwaba P, Maeurer M, Zumla A. Clin Infect Dis. 2015 Oct 15;61(suppl 3):S102-S118.


Corticosteroid therapy for pneumonia. Zumla A, Bates M, Maeurer M. Lancet. 2015 Sep 5;386(9997):955


Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. Zumla A, Azhar EI, Arabi Y, Alotaibi B, Rao M, McCloskey B, Petersen E, Maeurer M. Int J Infect Dis. 2015 Sep 10


Biomarkers for risk of developing active tuberculosis in contacts of TB patients: a prospective cohort study. Rakotosamimanana N, Richard V, Raharimanga V, Gicquel B, Doherty TM, Zumla A, Rasolofo Razanamparany V. Eur Respir J. 2015 Aug 6.


Ebola: missed opportunities for Europe-Africa research. Ippolito G, Lanini S, Brouqui P, Di Caro A, Vairo F, Abdulla S, Fusco FM, Krishna S, Capobianchi MR, Kyobe-Bosa H, Lewis DJ, Puro V, Wolfel R, Avsic-Zupanc T, Dar O, Mwaba P, Bates M, Heymann D, Zumla A. Lancet Infect Dis. 2015 Jul 28. 


Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates. Zumla A, Maeurer M; and the Host-Directed Therapies Network (HDT-NET) Consortium; and the Host-Directed Therapies Network HDT-NET Consortium.Clin Infect Dis. 2015 Jul 28. 


Towards host-directed therapies for tuberculosis. Zumla A, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS, Maeurer M. Nat Rev Drug Discov. 2015 Jul 17.


Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Uthman OA, Okwundu C, Gbenga K, Volmink J, Dowdy D, Zumla A, Nachega JB. Ann Intern Med. 2015 Jul 7;163(1):32-39. PDF


Middle East Respiratory Syndrome - need for increased vigilance and watchful surveillance for MERS-CoV in sub-Saharan African Africa. Zumla A, Rustomjee R, Ntoumi F, Mwaba P, Bates M, Maeurer M, Hui DS, Petersen E. Int J Infect Dis. 2015 Jun 30. PDF


Be prepared: Europe needs Ebola outbreak consortium. Zumla A, Heymann D, Ippolito G. Nature. 2015 Jul 1;523(7558):35. 


Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. Kroidl I, Clowes P, Reither K, Mtafya B, Rojas-Ponce G, Ntinginya EN, Kalomo M, Minja LT, Kowuor D, Saathoff E, Kroidl A, Heinrich N, Maboko L, Bates M, O'Grady J, Zumla A, Hoelscher M, Rachow A. Eur Respir J. 2015 Jun 25


A comparison of established diagnostic methodologies and a novel bacterial smpB real-time PCR assay for the specific detection of Haemophilus influenzae associated with respiratory tract infections. Reddington K, Schwenk S, Tuite N, Platt G, Davar D, Coughlan H, Personne Y, Gant V, Enne VI, Zumla A, Barry T. J Clin Microbiol. 2015 Jun 24


Middle East Respiratory Syndrome- advancing the public health and research agenda on MERS- lessons from the South Korea outbreak. Petersen E, Hui DS, Perlman S, Zumla A. Int J Infect Dis. 2015 Jun 10;36:54-55. 


Spread of MERS to South Korea and China. Hui DS, Perlman S, Zumla A. Lancet Respir Med. 2015 Jun 4.


Middle East respiratory syndrome. Zumla A, Hui DS, Perlman S. Lancet. 2015 Jun 3. pii: S0140-6736(15)60454-8.


Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32. Maeurer M, Rao M, Zumla A. Ann Transl Med. 2015 May;3(Suppl 1):S37. 


Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study. Bates M, Mudenda V, Shibemba A, Kaluwaji J, Tembo J, Kabwe M, Chimoga C, Chilukutu L, Chilufya M, Kapata N, Hoelscher M, Maeurer M, Mwaba P, Zumla A. Lancet Infect Dis. 2015 Mar 9. PDF


IFN-γ Release Assays for Risk Assessment in Contacts of Patients with Tuberculosis in Low-Burden European Countries. Zumla A, Maeurer M. Am J Respir Crit Care Med. 2015 May 15;191(10):1101-1103.


Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? Lanini S, Zumla A, Ioannidis JP, Caro AD, Krishna S, Gostin L, Girardi E, Pletschette M, Strada G, Baritussio A, Portella G, Apolone G, Cavuto S, Satolli R, Kremsner P, Vairo F, Ippolito G.

Lancet Infect Dis. 2015 Apr 13.


Lessons for Tuberculosis from scrutiny of HIV/AIDS and Malaria UK Parliamentary Questions. Oliver M, Craig GM, Zumla A. Int J Infect Dis. 2015 Mar;32:191-195.


Why healthcare workers are sick of TB. von Delft A, Dramowski A, Khosa C, Kotze K, Lederer P, Mosidi T, Peters JA, Smith J, van der Westhuizen HM, von Delft D, Willems B, Bates M, Craig G, Maeurer M, Marais BJ, Mwaba P, Nunes EA, Nyirenda T, Oliver M, Zumla A. Int J Infect Dis. 2015 Mar;32:147-51


Perspectives on tuberculosis in pregnancy. Bates M, Ahmed Y, Kapata N, Maeurer M, Mwaba P, Zumla A. Int J Infect Dis. 2015 Mar;32:124-7. 


The social context of tuberculosis treatment in urban risk groups in the United Kingdom: a qualitative interview study. Craig GM, Zumla A. Int J Infect Dis. 2015 Mar;32:105-10. 


Imaging in tuberculosis. Skoura E, Zumla A, Bomanji J. Int J Infect Dis. 2015 Mar;32:87-93. 


New tuberculosis diagnostics and rollout. McNerney R, Cunningham J, Hepple P, Zumla A. Int J Infect Dis. 2015 Mar;32:81-86. 


Surgical Treatment of Complications of Pulmonary Tuberculosis, including Drug-Resistant Tuberculosis. Madansein R, Parida S, Padayatchi N, Singh N, Master I, Naidu K, Zumla A, Maeurer M.

Int J Infect Dis. 2015 Mar;32:61-67. 


Tackling the Tuberculosis Epidemic in sub-Saharan Africa - unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024. Zumla A, Petersen E, Nyirenda T, Chakaya J. Int J Infect Dis. 2015 Mar;32:46-9. 


Cellular therapy in Tuberculosis. Parida SK, Madansein R, Singh N, Padayatchi N, Master I, Naidu K, Zumla A, Maeurer M. Int J Infect Dis. 2015 Mar;32:32-8.


Host-directed therapies for tuberculous pericarditis. Zumla A, Maeurer M, Moll G, Mayosi BM. Int J Infect Dis. 2015 Mar;32:30-1. 


Frequency of Mycobacterium tuberculosis-specific CD8+ T-cells in the course of anti-tuberculosis treatment. Axelsson-Robertson R, Rao M, Loxton AG, Walzl G, Bates M, Zumla A, Maeurer M.

Int J Infect Dis. 2015 Mar;32:23-9. 


Mycobacterium tuberculosis-specific and MHC class I-restricted CD8+ T-cells exhibit a stem cell precursor-like phenotype in patients with active pulmonary tuberculosis. Axelsson-Robertson R, Ju JH, Kim HY, Zumla A, Maeurer M. Int J Infect Dis. 2015 Mar;32:13-22. 


Commemorating world tuberculosis day 2015. Zumla A, Maeurer M, Marais B, Chakaya J, Wejse C, Lipman M, McHugh TD, Petersen E. Int J Infect Dis. 2015 Mar;32:1-4. 


Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies. Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, Kapata N, Nyirenda T, Chanda D, Mfinanga S, Hoelscher M, Maeurer M, Migliori GB. Lancet Respir Med. 2015 Mar;3(3):220-34.


Respiratory tract infections in community and healthcare settings: epidemiological, diagnostic and management challenges. Zumla A, Niederman MS. Curr Opin Pulm Med. 2015 Mar 16.


Emerging respiratory tract viral infections. Hui DS, Zumla A. Curr Opin Pulm Med. 2015 Mar 11. 


Impact of the Xpert MTB/RIF diagnostic test for tuberculosis in countries with a high burden of disease. McNerney R, Zumla A. Curr Opin Pulm Med. 2015 Mar 11.


Host-directed therapy: tuberculosis vaccine development. Rao M, Zumla A, Maeurer M. Lancet Respir Med. 2015 Feb 25. 


Tuberculosis Comorbidity with Communicable and Noncommunicable Diseases. Bates M, Marais BJ, Zumla A. Cold Spring Harb Perspect Med. 2015 Feb 6. pii: a017889.


Clinical Aspects of Adult Tuberculosis. Loddenkemper R, Lipman M, Zumla A. Cold Spring Harb Perspect Med. 2015 Feb 6. pii: a017848.


Middle East respiratory syndrome in the shadow of Ebola. Zumla A, Perlman S, McNabb SJ, Shaikh A, Heymann DL, McCloskey B, Hui DS. Lancet Respir Med. 2015 Jan 12. pii: S2213-2600(14)70316-9. doi: 10.1016/S2213-2600(14)70316-9. 


TB-HAART trial - Authors' reply. Mfinanga SG, Kirenga BJ, Chanda DM, Connolly C, Mwaba P, Joloba M, Zumla A; TB-HAART Study Group. Lancet Infect Dis. 2015 Jan;15(1):15-6. doi: 10.1016/S1473-3099(14)71051-5.


The WHO 2014 Global tuberculosis report-further to go. Zumla A, George A, Sharma V, Herbert RH; Baroness Masham of Ilton, Oxley A, Oliver M. Lancet Glob Health. 2015 Jan;3(1):e10-2. doi: 10.1016/S2214-109X(14)70361-4. 


Genesis of EDCTP2. Zumla A, Makanga M, Nyirenda T, Beattie P, Olesen OF, Breugelmans JG, Aklillu E, Corrah T, Mgone C. Lancet Infect Dis. 2015 Jan;15(1):11-3.


Prevalence and Risk Factors for Betaherpesvirus DNAemia in Children >3 Weeks and <2 Years of Age Admitted to a Large Referral Hospital in Sub-Saharan Africa. Tembo J, Kabwe M, Chilukutu L, Chilufya M, Mwaanza N, Chabala C, Zumla A, Bates M. Clin Infect Dis. 2015 Feb 1;60(3):423-31


An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in jeddah and riyadh, kingdom of saudi arabia, 2014. Drosten C, Muth D, Corman VM, Hussain R, Al Masri M, HajOmar W, Landt O, Assiri A, Eckerle I, Al Shangiti A, Al-Tawfiq JA, Albarrak A, Zumla A, Rambaut A, Memish ZA. Clin Infect Dis. 2015 Feb 1;60(3):369-77.